Sumatriptan
Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size. Available in tablet, nasal spray, and injectable forms, it is most effective when taken at the first sign of a migraine.
Berat Molekul
295,4020 g/mol
LogP
0,90
TPSA
73,60 Ų
Lipinski RO5
Lulus
Area Terapeutik
Kelas Obat
Mekanisme Kerja
Selective 5-HT1B/1D receptor agonist.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective 5-HT1B/1D receptor agonist.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
InChI
InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3
Molecular Formula
C14H21N3O2S
HBD / HBA
2 / 4
Ikatan yang Dapat Dirotasi
6
Atom Berat
20
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.
Sertraline and sumatriptan may interact to increase serotonergic tone, raising the theoretical risk of serotonin syndrome.
Co-administration of escitalopram and sumatriptan may lead to serotonin syndrome, though clinical cases are less frequent than with tramadol combinations.
Fluoxetine plus sumatriptan may potentiate serotonin syndrome risk, though the clinical evidence is mixed and the absolute risk is debated.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Designed specifically for migraine attacks, this triptan medication works by activating serotonin receptors in the brain and blood vessels, causing the swollen blood vessels responsible for migraine pain to constrict back to normal size. Available in tablet, nasal spray, and injectable forms, it is most effective when taken at the first sign of a migraine.
Selective 5-HT1B/1D receptor agonist.
Key pharmacokinetic parameters for Sumatriptan: Half-life: 2.5 hours.
Yes, Sumatriptan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL128. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5358. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sumatriptan"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sumatriptan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sumatriptan/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sumatriptan/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sumatriptan"></drugfyi-drug>